170 related articles for article (PubMed ID: 24168624)
21. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
[TBL] [Abstract][Full Text] [Related]
22. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
23. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
[TBL] [Abstract][Full Text] [Related]
24. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications.
Chen G; Shukeir N; Potti A; Sircar K; Aprikian A; Goltzman D; Rabbani SA
Cancer; 2004 Sep; 101(6):1345-56. PubMed ID: 15316903
[TBL] [Abstract][Full Text] [Related]
25. Expression of tumor-associated glycoprotein 72 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
Myers RB; Schlom J; Srivastava S; Grizzle WE
Mod Pathol; 1995 Apr; 8(3):260-5. PubMed ID: 7617651
[TBL] [Abstract][Full Text] [Related]
26. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
27. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
[TBL] [Abstract][Full Text] [Related]
28. Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ.
Hou H; Chen W; Zhao L; Zuo Q; Zhang G; Zhang X; Wang H; Gong H; Li X; Wang M; Wang Y; Li X
J Clin Pathol; 2012 Dec; 65(12):1088-96. PubMed ID: 22944623
[TBL] [Abstract][Full Text] [Related]
29. Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy.
Amin A; Partin A; Epstein JI
J Urol; 2011 Oct; 186(4):1286-90. PubMed ID: 21862072
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
[TBL] [Abstract][Full Text] [Related]
31. Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level.
McGuire BB; Helfand BT; Loeb S; Hu Q; O'Brien D; Cooper P; Yang X; Catalona WJ
BJU Int; 2012 Jun; 109(12):1764-9. PubMed ID: 22017732
[TBL] [Abstract][Full Text] [Related]
32. Correlation between the preoperative serum prostate specific antigen, Gleason score, and clinical staging with pathological outcome following robot-assisted radical prostatectomy: an Indian experience.
Singh P; Dogra PN; Gupta NP; Nayyar R; Seth A; Javali TD; Kumar R
Indian J Cancer; 2011; 48(4):483-7. PubMed ID: 22293265
[TBL] [Abstract][Full Text] [Related]
33. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
[TBL] [Abstract][Full Text] [Related]
34. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis.
Erdamar S; Yang G; Harper JW; Lu X; Kattan MW; Thompson TC; Wheeler TM
Mod Pathol; 1999 Aug; 12(8):751-5. PubMed ID: 10463475
[TBL] [Abstract][Full Text] [Related]
35. Serum prostate-specific antigen and the biologic progression of prostate cancer.
Kabalin JN; McNeal JE; Johnstone IM; Stamey TA
Urology; 1995 Jul; 46(1):65-70. PubMed ID: 7541589
[TBL] [Abstract][Full Text] [Related]
36. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
[TBL] [Abstract][Full Text] [Related]
37. c-met proto-oncogene expression in benign and malignant human prostate tissues.
Pisters LL; Troncoso P; Zhau HE; Li W; von Eschenbach AC; Chung LW
J Urol; 1995 Jul; 154(1):293-8. PubMed ID: 7539865
[TBL] [Abstract][Full Text] [Related]
38. Predicting pelvic lymph node involvement in current-era prostate cancer.
Rahman S; Cosmatos H; Dave G; Williams S; Tome M
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):906-10. PubMed ID: 21300478
[TBL] [Abstract][Full Text] [Related]
39. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
40. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]